Biotech

Dyne Therapeutics (DYN) Stock Slides After $300 Million Offering as Duchenne Trial Data Drives Bullish Street Targets

December 9, 2025 — Dyne Therapeutics, Inc. (NASDAQ: DYN) shares were volatile on Tuesday, giving back part of a recent rally even as Wall Street responded positively to new clinical data and raised price targets on the neuromuscular‑disease biotech. In

9 December 2025

Therapeutics (KYMR) Stock Rockets on KT‑621 Eczema Breakthrough, Then Pauses After $500M Share Offering – 9 December 2025 Update

Updated: December 9, 2025 Kymera Therapeutics’ stock has just done the biotech equivalent of a backflip: a ~40–50% one‑day surge on Monday after stunning eczema trial data, followed almost immediately by a cool‑down triggered by a $500 million stock offering

9 December 2025

Biotechnology · Healthcare News · Investment · Pharmaceutical Industry · Stock Market

Structure Therapeutics (GPCR) Stock Explodes on Obesity Pill Breakthrough: Latest News, Analyst Targets and 2026–2035 Outlook

Structure Therapeutics Inc. (NASDAQ: GPCR) has suddenly become one of the most talked‑about obesity‑drug names on Wall Street. As of mid‑day on December 9, 2025, Structure Therapeutics stock was trading around $69.98, up roughly 100% in a single session after

9 December 2025

Analyst Forecasts · Biotechnology · NASDAQ:GPCR · Obesity Treatments · Pharmaceutical Industry · Stock News

Tokyo Stock Market’s Biggest Losers Today (December 9, 2025): Growth, Biotech and Small Caps Take the Hit

Tokyo’s stock market spent Tuesday trading near record highs – but beneath the calm surface, a wave of heavy selling hit some of the market’s riskiest names. While the Nikkei 225 hovered around the 50,700 level, up roughly 0.2% on

9 December 2025

Biotech Stocks · Growth Stocks · Market Losers · Small Caps · Tokyo Stock Exchange

CSL Limited (ASX:CSL) Stock Outlook 2026: Is the Biotech Giant Finally a Buy After a 35% Sell-Off?

As of 9 December 2025 CSL Limited, long considered one of the most reliable growth names on the ASX, has just lived through one of the ugliest years in its listed history. After profit downgrades, a delayed spin-off, falling US

9 December 2025

ASX · Biotech · Investing · Market Analysis · Stocks

Biggest Stock Gainers Today: Biotech Breakouts and IBM–Confluent Deal Lead U.S. Market Movers (December 8, 2025)

U.S. stocks traded mostly flat on Monday as Wall Street headed into a crucial Federal Reserve meeting, but under the surface the tape was anything but quiet. While the S&P 500 and Dow Jones Industrial Average hovered around unchanged and

8 December 2025

Biotech · Investment News · Market Analysis · Mergers & Acquisitions · NASDAQ:CETX · NASDAQ:CFLT · NASDAQ:FULC · NASDAQ:GPCR · NASDAQ:WVE · NYSE:IBM · Stock Market

Top Pre‑Market Gainers Today (December 8, 2025): Confluent, Carvana and Biotech Names Lead Fed‑Week Rally

U.S. stock futures are edging higher on Monday, December 8, 2025, as traders head into a pivotal Federal Reserve meeting widely expected to deliver this year’s final rate cut. Nasdaq 100 futures are up around a quarter of a percent,

8 December 2025

Biotech Stocks · Financial News · Investing · NASDAQ:ACLX · NASDAQ:AVGO · NASDAQ:CFLT · NASDAQ:DYN · NASDAQ:FULC · NASDAQ:HOOD · NASDAQ:KYMR · NASDAQ:MU · NASDAQ:OCUL · NASDAQ:RGNX · NASDAQ:TER · NYSE:ALB · NYSE:CVNA · NYSE:IBM · Pre-Market Movers · Stock Market

NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

Data and news current as of 7 December 2025. NVAX stock price now: where Novavax stands in December 2025 Novavax, Inc. (NASDAQ: NVAX) closed on Friday, 5 December 2025 at $6.91 per share, giving the vaccine maker a market value

7 December 2025

Biotech · Investing · Market Analysis · NASDAQ:NVAX · Pharma Industry · Stocks

Moderna (MRNA) Stock Jumps on Vaccine Safety Study and $1.5B Lifeline: Latest News and Forecasts as of December 6, 2025

Moderna Inc. (NASDAQ: MRNA) is back in the spotlight. After months of pressure from collapsing COVID‑19 vaccine demand and rising regulatory scrutiny, the stock has staged a sharp rebound in early December 2025 — powered by a major long‑term safety

6 December 2025

Biotechnology · Financial Forecasts · Market News · NASDAQ:MRNA · Stocks · Vaccines

Moderna (MRNA) Stock: French Study Sparks Rally After FDA Shock – Latest News, Analyst Forecasts and 2026 Outlook

Updated: December 6, 2025 Moderna, Inc. (NASDAQ: MRNA) has just had one of its most dramatic weeks of 2025. Shares plunged early in the week after news that the U.S. Food and Drug Administration (FDA) may tighten vaccine approval standards,

6 December 2025

Analysis · Biotech · Forecasts · Market News · NASDAQ:MRNA · Stocks

Aditxt (ADTX) Stock on December 5, 2025: BitXbio Pivot, Reverse Split and Survival Risk Explained

Published: December 5, 2025 Key Takeaways This article summarizes the latest news, forecasts, and analyses on Aditxt, Inc. (NASDAQ: ADTX) as of December 5, 2025, based on regulatory filings, company press releases and market data. It is informational only and

5 December 2025

Biotechnology · Company Analysis · Financial News · Investment Insights · NASDAQ:ADTX · Stock Market

IonQ Stock (IONQ) on December 5, 2025: Quantum Breakthroughs, Biotech Deals, Big Money Flows and 2026 Forecast

IonQ, Inc. (NYSE: IONQ) is back in the spotlight today after another burst of volatility that has pushed the stock to around the low‑$50s per share as of December 5, 2025. Different data sources show IONQ trading in the $51–55

5 December 2025

NYSE:IONQ